Statins News From Medical News TodayLatest Statins News From Medical News Today.Statins Linked To Lower Dementia Risk- July 29, 2008 A US study that followed over 1,500 older Mexican Americans for 5 years found that statin users were about half as likely to develop dementia, or to have cognitive impairment without dementia, as those who did not use statins. Statins are normally prescribed for lowering LDL or "bad" cholesterol.http://www.medicalnewstoday.com/articles/116410.php Alzheimer's Society Comment On Research Into Statins And Dementia- July 29, 2008 Statins are increasingly hitting the headlines as a potential cure for dementia. The jury is still out on how effective they are, but this study adds to growing evidence that they may have some benefits. All drugs have some side-effects so it is important to seek professional advice about medication.http://www.medicalnewstoday.com/articles/116412.php Statins May Protect Against Memory Loss- July 29, 2008 People at high risk for dementia who took cholesterol-lowering statins are half as likely to develop dementia as those who do not take statins, a new study shows. The study consisted of older Mexican-Americans in Sacramento, Calif.http://www.medicalnewstoday.com/articles/116401.php New Data On Average National Cholesterol Levels Provides Benchmark To Measure Progress To Treatment Targets, UK- July 29, 2008 New research from over 223,000 patients published in the Primary Care Cardiovascular Journal (PCCJ)1, suggests that total cholesterol (TC) levels in statin-treated UK patients are higher than that of the general population. The recent Health Survey for England (HSE 2006) 2 found that the mean TC was 5.3 mmolL in men and 5.4 mmolL in women. This is in contrast to the average TC of 6.http://www.medicalnewstoday.com/articles/116357.php 'Statins' Linked To Improved Survival In Kidney Transplant Recipients- July 24, 2008 For patients receiving kidney transplants, treatment with cholesterol-lowering "statin" drugs may lead to longer survival, reports a study in the November 2008 Journal of the American Society of Nephrology (JASN). "Statin therapy is well established for the primary and secondary prevention of cardiovascular disease in the general population, but its effectiveness in patients with kidney disease is unclear," comments Dr.http://www.medicalnewstoday.com/articles/115973.php Results From The SEAS (Simvastatin And Ezetimibe In Aortic Stenosis) Study- July 22, 2008 The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) in patients with aortic stenosis. Aortic stenosis (which involves partial blockage of the aortic valve in the heart) is a relatively common disease among older people in Western populations. Left untreated, it can progress to death from heart failure or cardiac arrest.http://www.medicalnewstoday.com/articles/115715.php Independent Analyses Of The SEAS, SHARP And IMPROVE-IT Studies Of Statin Ezetimibe- July 22, 2008 The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) proposed that the hypothesis-generating results of the SEAS trial of ezetimibe should be tested by reviewing the combined cancer results from the SHARP and IMPROVE-IT trials of ezetimibe, and reporting on the overall findings to the relevant regulatory authorities, independently of the drug manufacturers.http://www.medicalnewstoday.com/articles/115713.php Mitochondrial Cholesterol Makes Response To Chemotherapy Difficult In Hepatic Cancer- July 15, 2008 Cancer is a disease characterized by important metabolic alterations. Not only do these adaptative changes give higher proliferative capacity to cancer cells, but they also contribute to higher resistance to chemotherapeutic agents. The research group led by Dr.http://www.medicalnewstoday.com/articles/115063.php TREDAPTIVETM (Nicotinic Acid Laropiprant) Approved In The European Union: New Lipid-Modifying Therapy To Treat LDL-C, HDL-C And Triglycerides- July 14, 2008 Merck Sharp & Dohme (MSD) announced that TREDAPTIVE (nicotinic acidlaropiprant, MSD) 1 g20 mg modified-release tablets, a new lipid-modifying therapy for patients with dyslipidemia and primary hypercholesterolemia, has been approved for marketing in the European Union (EU), Iceland and Norway. TREDAPTIVE combines nicotinic acid (niacin) and laropiprant, a novel flushing pathway inhibitor.http://www.medicalnewstoday.com/articles/114885.php Fish Oil And Red Yeast Rice Studied For Lowering Blood Cholesterol- July 9, 2008 A great deal of scientific evidence shows that cholesterol-reducing medications known as statins can help prevent coronary artery disease. Although the safety of these medications has been well documented, as many as 40 percent of patients who receive a prescription for statins take the drug for less than one year.http://www.medicalnewstoday.com/articles/114307.php |